| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Mizuho America is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Village Improvement Association of Doylestown is a Doylestown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediMedia Information Technologies (MMIT) was founded to assist health plans in the printing and distribution of their formulary documents. Over the last 25 years, MMIT has expanded and strengthened its relationships throughout the industry, developed innovative technology, and capitalized on trends to become the leading provider of multichannel formulary information solutions.
Medigraphics Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.